Q-Line Biotech Ltd. IPO

We are engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. Our company supplies ... diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through our distributor/s majorly to diagnostic service providers, hospitals and medical colleges. The company has established its brands over a period of 12 years through its experience, R & D, manufacturing capabilities and quality assurance. The core segments of operations of our Company in IVD Industry include Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids). Our key manufacturing segments include indigenous manufacturing of reagents including Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids) and supplying/ manufacturing of in-vitro diagnostics (IVD), Pathology equipment’s & devices. Further during the Covid-19 pandemic, the company diversified its focus and with the technical collaboration of third-party institutes and through its own R&D team developed a range of Covid testing kits viz. RT-PCR Kits, RNA Extraction Kits, VTM Kits etc. We are research driven company engaged in developing and manufacturing a wide range of reagents formulations used across various IVD and diagnostic needs. We leverage our R&D capabilities to develop and manufacture a portfolio of differentiated reagent formulations /products. Further, for our certain Class of Reagent & equipment’s and devices manufacturing business, the company has entered into technical collaboration with certain international companies. Under the agreement terms, we undertake the manufacturing of these Reagent and equipment’s and devices as per the technical collaboration and specifications provided by the partners or companies. With the help of these collaborations the equipment and devices adhere to strict quality control, international standards and certifications. As of March 31, 2026, we employed 19 personnel at our R&D laboratories, which constituted 5.25% of our total permanent employee strength. Further, for the Make in India instruments, we are working on the following projects: • Selectra Pro M: We are currently manufacturing the Selectra Pro M—a medium-throughput, fully automatic clinical chemistry analyser—in India under a technical collaboration with one of the European companies. This instrument has been successfully scaled up for commercial production and is already serving laboratories across multiple regions. • Selectra Pro XL - Building on our partnership, we are developing “Make in India” prototype of Selectra Pro XL which is a high-throughput, fully automatic clinical chemistry analyser designed for large laboratories and hospital networks. The prototype in advanced stages of development and will undergo internal validation before moving to formal approval. • Microlab 300 - This device is currently undergoing regulatory review and approval. Once cleared, it will expand our portfolio into the semi-automatic analyser market for clinical chemistry • Medonic M20: we have completed the development of the Medonic M20 three-part haematology analyser prototype. This device has passed both the regulatory and quality approval. Currently our staff is undergoing the required training for manufacturing, and we expect the commercial production for this to go live in Q2 FY26-27. • KC1 Delta: we have also developed a prototype of the KC1 Delta coagulation analyser. This instrument is currently under review with the relevant authorities and is expected to enter the market upon receipt of the requisite approvals. • Innolyte: Demonstrating our in-house R&D capabilities, we have indigenously developed the Innolyte electrolyte analyser with commercial production started in March 2026. • Slide Stainer - we have indigenously developed the slide stainer and currently we are in the process of evaluating the reuse of stains and the commercial production of this instrument is expected to go line in Q3 of FY26-27. • Q-Count 5: Currently under development, will be our indigenous 5-part haematology analyser. Read more

The IVD industry in India is experiencing a significant transformation, driven by multiple factors that are reshaping the landscape of healthcare diagnostics. Diagnostic testing has always been a crucial aspect of healthcare, enabling medical professionals to identify conditions accurately and ... determine appropriate treatments. The COVID-19 pandemic, although it led to an initial surge in demand for IVD products, continues to influence the market, with growth stabilizing following a decline in cases. However, the underlying momentum for growth remains strong due to evolving healthcare needs and improvements in accessibility. As India’s population grows and life expectancy increases, the demand for diagnostic solutions continues to rise. Better accessibility to healthcare services, the increasing burden of chronic diseases such as diabetes, cardiovascular diseases, and cancer, and a growing focus on preventative healthcare are transforming the market. The changing attitudes towards early disease detection and proactive health management have also contributed to this trend, shifting the emphasis from treatment to prevention. Government policies such as Make in India, Atmanirbhar Bharat, and Ayushman Bharat have provided significant support to the Indian IVD industry. These initiatives have encouraged the development of affordable, high-quality indigenous products, making India less reliant on imports and more self-sufficient in meeting domestic demand. As a result, the Indian IVD market is poised to make its mark globally, with the potential for increased exports and international partnerships. The next-generation IVD market is booming, fueled by the rise in infectious diseases, increased awareness, and the growing demand for personalized healthcare. Consumers and healthcare providers are increasingly focused on early detection, creating a surge in demand for diagnostic solutions that can identify health issues at the earliest stages. This demand is amplified by advances in technology from automation and digitization to the development of customized diagnostic tools. Several key drivers are contributing to the rapid growth of the IVD market in India. Technological advancements, such as automation, multiplex panel testing, and Point-of-Care (POC) diagnostics, are revolutionizing early disease detection and prevention. These innovations are enabling faster, more accurate testing, reducing the time between diagnosis and treatment. Furthermore, the increased reliance on IVD by biotech sectors, along with a surge in investments and R&D in diagnostics, is fostering innovation and improving diagnostic capabilities. Geopolitical tensions in West Asia may lead to risks for the Indian in-vitro diagnostics (IVD) industry through disruptions in global supply chains, changes in freight and input costs, and delays in the procurement of reagents and equipment. The industry is supported by healthcare awareness, diagnostic penetration, and demand for preventive and routine testing. While these factors may affect margins and operational efficiency in the short term, the domestic demand base and localisation of manufacturing may support stability over the medium term. The future of the Indian IVD industry is promising. With continued advancements in diagnostic technologies, greater adoption of automation and digital health solutions, and a focus on accessibility, the industry is well-positioned for sustained growth. As India continues to evolve into a global player in diagnostics, its ability to provide affordable and high-quality solutions will be a critical factor in shaping the future of healthcare both domestically and internationally. The demand for rapid, accurate, and personalized diagnostic solutions will drive the industry forward, with a strong focus on preventative care, early detection, and disease management. Read more